The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study
Open accessAbstract
In recent years the use of immunomodulating therapy to treat various cancers has been on the rise. Three checkpoint inhibitors have been approved by the Food and Drug Administration (ipilimumab, pembrolizumab and nivolumab). The use of these drugs comes with serious adverse events related to excessive immune activation, collectively known as immune-related adverse events (irAEs). We conducted a system-based review of 139 case reports/case series that have described these adverse events between January 2016 and April 2018, found in the PubMed database. There was a broad spectrum of presentations, doses and checkpoint inhibitors used. The most common check point inhibitor observed in our literature review was nivolumab. The most common adverse effects encountered were colitis (14/139), hepatitis (11/139), adrenocorticotropic hormone insufficiency (12/139), hypothyroidism (7/139), type 1 diabetes (22/139), acute kidney injury (16/139) and myocarditis (10/139). The treatment most commonly consisted of cessation of the immune checkpoint inhibitor, initiation of steroids and supportive therapy. This approach provided a complete resolution in a majority of cases; however, there were many that developed long-term adverse events with deaths reported in a few cases. The endocrine system was the mostly commonly affected with the development of type 1 diabetes mellitus or diabetic ketoacidosis being the most frequently reported adverse events. While immunomodulating therapy is a significant advance in the management of various malignancies, it is capable of serious adverse effects. Because the majority of the cases developed pancreatic dysfunction within five cycles of therapy, in addition to the evaluation of other systems, pancreatic function should be closely monitored to minimize adverse impact on patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“overactivation of the immune system to boost antitumor immunity can act as a double-edged sword, leading to the development of irAEs that can range from mild rash to severe colitis to life-threatening myocarditis (114, 115).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“30-60% of patients experience irAEs of any grade”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
Experimental — accuracy not yet measuredIn the citing paper
“approximately 10-20% experience more severe grade 3 or 4 irAEs”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
In the citing paper
“Newly developed autoimmune disease, such as type I diabetes in patients with no prior history of the disease, following checkpoint therapy has also been reported to occur”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 2×
“This over-activation can potentially affect multiple organ systems including the gastrointestinal tract, kidneys, nervous system, liver, eyes, skin, pancreas and endocrine system [8-12].”
BackgroundThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 4×
“This over-activation can potentially affect multiple organ systems including the gastrointestinal tract, kidneys, nervous system, liver, eyes, skin, pancreas and endocrine system [8-12].”
BackgroundInfluentialFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · cited 4×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundInfluentialThe Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814 · cited 1×
“This process is regulated by stimulatory, co-stimulatory, and inhibitory (checkpoint) signals [4-6].”
BackgroundBertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704 · cited 1×
“Many of the conditions can be life-threatening calling for discontinuation of treatment, long-term corticosteroids and at times anti-tumor necrosis factor therapy [13].”
BackgroundOkazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., et al. (2003) · Nature Medicine · doi:10.1038/nm955 · Cited by 689 · cited 1×
“Another study published in Nature Medicine reported that mice deficient in the PD-1 immuno-inhibitory co-receptor develop autoimmune dilated cardiomyopathy with production of high titer autoantibodies against a heart specific protein [115].”
BackgroundImmune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 515 · cited 4×
“The patients who received FDA-approved checkpoint inhibitors such as ipilimumab, pembrolizumab and nivolumab were considered whether they received the treatment in a clinical trial or as part of standard of care.”
BackgroundInfluentialCardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511 · cited 3×
“The cases are illustrated in Table 3 below [95-102].”
Background
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 293
Teixeira, A. F., ten Dijke, P., & Zhu, H.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00605 · Cited by 211
D’Souza, M., Nielsen, D., Svane, I. M., Iversen, K., Rasmussen, P. V., Madelaire, C., Fosbøl, E., Køber, L., Gustafsson, F., Andersson, C., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa884 · Cited by 171
Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer
Jin, X., Liu, Z., Yang, D., Yin, K., & Chang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948647 · Cited by 146
Stelmachowska‐Banaś, M., & Czajka-Oraniec, I. (2020) · Endocrine Connections · doi:10.1530/ec-20-0342 · Cited by 145
Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options
Kohoutová, D., Worku, D. A., Aziz, H., TEARE, J. P., Weir, J., & Larkin, J. (2021) · Cells · doi:10.3390/cells10020327 · Cited by 111
“A retrospective study showed that the most common adverse events were colitis, hepatitis, adrenocorticotropic hormone insufficiency, and hypothyroidism, followed by type 1 diabetes, acute kidney injury, and myocarditis [64].”
BackgroundImmunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 71
Immune checkpoint inhibitors in lymphoma: challenges and opportunities
Hatic, H., Sampat, D., & Goyal, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6833 · Cited by 72
“IrAEs reflect an “over-stimulated” immune system that can affect any body part and most commonly comprise dermatological (rash/dermatitis), gastrointestinal (colitis, hepatitis, pancreatitis), pulmonary (pneumonitis) and endocrine (thyroid, hypophysitis/adrenal crisis) sideeffects (114).”
BackgroundUnraveling exhaustion in adaptive and conventional NK cells
Merino, A. M., Kim, H., Miller, J. S., & Cichocki, F. M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr0620-091r · Cited by 69
Lima‐Sousa, R., Melo, B. L., Alves, C. G., Moreira, A. F., Mendonça, A., Correia, I. J., & de Melo‐Diogo, D. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202010777 · Cited by 66
IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma
Kishi, S., Minato, M., Saijo, A., Murakami, N., Tamaki, M., Matsuura, M., Murakami, T., Nagai, K., Abe, H., Nishioka, Y., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9814-17 · Cited by 66
Liu, Y., Zhang, H., Zhou, L., Li, W., Yang, L., Li, W., Li, K., & Liu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627612 · Cited by 65
“(16) M (12) F (9) Lung cancer (5) Melanoma (9) Breast cancer (2) RCC (1) Multiple myeloma (1) Lymphoma (1) MCC (1) Esophageal cancer (1) Pancreatic cancer (1) NR Pembrolizumab 8.”
BackgroundAlmawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Jiang, M., Hu, Y., Lin, G., & Chen, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906251 · Cited by 71
Ferreira, J. L., Costa, C. F., Marques, B., Castro, S., Víctor, M., Oliveira, J., Santos, A. P., Sampaio, I. L., Duarte, H., Marques, A. P., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02664-y · Cited by 59
Makunts, T., Saunders, I. M., Cohen, I. V., Li, M., Moumedjian, T., Issa, M. A., Burkhart, K., Lee, P., Patel, S. P., & Abagyan, R. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-96467-5 · Cited by 59
Self-citationSlevin, S. M., Garner, L. C., Lahiff, C. J., Tan, M. T. K., Wang, L. M., Ferry, H., Greenaway, B., Lynch, K. D., Geremia, A., Hughes, S. A., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa054 · Cited by 55
Yao, L., Jia, G., Lu, L., Bao, Y., & Ma, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106628 · Cited by 55
Kariri, Y. A., Aleskandarany, M. A., Joseph, C., Kurozumi, S., Mohammed, O. J., Toss, M. S., Green, A. R., & Rakha, E. A. (2020) · Pathobiology · doi:10.1159/000508337 · Cited by 54
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study
Koks, M., Ocak, G., Suelmann, B. B. M., Hulsbergen-Veelken, C. A. R., Haitjema, S., Vianen, M. E., Verhaar, M. C., Kaasjager, K. A. H., & Khairoun, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252978 · Cited by 54
“These immune-related adverse events (irAE) may affect multiple organ systems, typically involving the skin, gastrointestinal tract, liver, and endocrine system [10,11].”
BackgroundChen, J., Li, S., Yao, Q., Du, N., Fu, X., Lou, Y., Wang, M., Mao, F., Mao, D., Khadaroo, P. A., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01933-5 · Cited by 48
Photothermal therapies to improve immune checkpoint blockade for cancer
Balakrishnan, P. B., Sweeney, E. E., Ramanujam, A. S., & Fernandes, R. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1797190 · Cited by 48
“Additionally, ICB mAbs can generate dose-limiting and sometimes toxic immune-related adverse effects [23,24].”
Walters, A. A., Santacana-Font, G., Li, J., Routabi, N., Qin, Y., Claes, N., Bals, S., Wang, J. T.-W., & Al‐Jamal, K. T. (2021) · ACS Nano · doi:10.1021/acsnano.1c04456 · Cited by 47
Bai, R., Chen, N., Chen, X., Li, L., Song, W., Li, W., Zhao, Y., Zhang, Y., Han, F., Lyu, Z., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0052 · Cited by 51
Inge, L. J., & Dennis, E. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.04.001 · Cited by 44
Species differences in immune‐mediated CNS tissue injury and repair: A (neuro)inflammatory topic
Healy, L. M., Yaqubi, M., Ludwin, S. K., & Antel, J. P. (2019) · Glia · doi:10.1002/glia.23746 · Cited by 44
“A challenge is whether animal-based studies will predict all the complications, including acute inflammation within the CNS (encephalomyelitis) (Bajwa et al., 2019; Leitinger et al., 2018).”
BackgroundZhang, W., Hwang, J., Yadav, D., An, E., Kwak, M., Lee, P. C.-W., & Jin, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179125 · Cited by 46
“It has well investigated that anti-PD-1 Ab can stimulate T cells for induction of anti-cancer immunity [55].”
BackgroundZhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 43
Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents
Andrés, M. V., Casadó‐Llombart, S., Català, C., Leyton-Pereira, A., Lozano, F., & Aranda, F. (2020) · Cells · doi:10.3390/cells9122589 · Cited by 39
“The use of a checkpoint inhibitor therapies has the downside of excessive immune activation, which can lead to immune-related adverse events (autoimmunity) [82].”
BackgroundEndocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
Rubino, R., Marini, A., Roviello, G., Presotto, E. M., Desideri, I., Ciardetti, I., Brugia, M., Pimpinelli, N., Antonuzzo, L., Mini, E., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02750-w · Cited by 38
Piscitani, L., Sirolli, V., Liberato, L. D., Morroni, M., & Bonomini, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144878 · Cited by 38
Immunotherapy-induced Hepatotoxicity: A Review
Cunha, T. D., Wu, G. Y., & Vaziri, H. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00105 · Cited by 49
Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, D., Zaheer, S., Sureka, N., Trisal, M., Chaurasia, J. K., & Zaheer, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155864 · Cited by 41
dos Anjos, G. R., Machado, G. F., de Barros, C. P., de Andrade, V. P., Maciel, R. M. B., & Cunha, L. L. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1601483 · Cited by 42
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
Nikoo, M., Rabiee, F., Mohebbi, H., Eghbalifard, N., Rajabi, H., Yazdani, Y., Sakhaei, D., Khosravifarsani, M., & Akhavan‐Sigari, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109881 · Cited by 35
Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity
Yang, X., Li, G., Yang, T., Guan, M., An, N., Yang, F., Dai, Q., Zhong, C., Luo, C., Gao, Y., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4894625 · Cited by 37
Ariyasu, H., Inaba, H., OTA, T., YAMAOKA, H., Furukawa, Y., Iwakura, H., Doi, N., Yamamoto, Y., & Akamizu, T. (2018) · In Vivo · doi:10.21873/invivo.11244 · Cited by 31
Using CRISPR to enhance T cell effector function for therapeutic applications
Heeren, J. J. F. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100049 · Cited by 32
Recent Advances in Cancer Immunotherapy Delivery Modalities
Muthukutty, P., Woo, H. Y., Murali, R., & Yoo, S. Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020504 · Cited by 33
FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects
Al‐Ibraheem, A., Abdlkadir, A. S., Juweid, M. E., Al-Rabi, K. H., Ma’koseh, M., Abdel‐Razeq, H., & Mansour, A. H. (2023) · Cancers · doi:10.3390/cancers15041063 · Cited by 30
Approach to the adult patient with chronic diarrhea: A literature review
Gomez-Escudero, O., & Remes-Troche, J. M. (2021) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2021.08.007 · Cited by 28
Cancer immunotherapy from biology to nanomedicine
Abdelbaky, S. B., Ibrahim, M. T., Samy, H., Mohamed, M., Mohamed, H., Mustafa, M., Abdelaziz, M. M., Forrest, M. L., & Khalil, I. A. H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.025 · Cited by 29
Assi, H. H., Wong, C., Tipton, K. A., Mei, L., Wong, K., Razo, J., Chan, C., Howng, B., Sagert, J., Krimm, M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0031 · Cited by 31
“A significant drawback to the administration of the mAb checkpoint inhibitors is the induction of systemic immune-related adverse events, which can be severe and life-threatening [3, 4].”
BackgroundGkiala, A., & Palioura, S. (2020) · Clinical ophthalmology · doi:10.2147/opth.s271569 · Cited by 28
Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis
Quiroga, D. M., Liebner, D. A., Philippon, J. S., Hoffman, S. E., Tan, Y., Chen, J. L., Lenobel, S. S., Wakely, P. E., Pollock, R. E., & Tinoco, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07021-x · Cited by 28
Biber, G., Ben‐Shmuel, A., Noy, E., Joseph, N., Puthenveetil, A., Reiss, N., Levy, O., Lazar, I., Feiglin, A., Ofran, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25842-7 · Cited by 26
Acute Kidney Injury Induced by Immune Checkpoint Inhibitors
Tian, R., Liang, J., Li, R., & Zhou, X. (2022) · Kidney Diseases · doi:10.1159/000520798 · Cited by 24
Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response
Wang, Y., Zhao, Y., Guo, W., Yadav, G. S., Bhaskarla, C., Wang, X., Wang, X., Li, S., Wang, Y., Chen, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.add0005 · Cited by 21
Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis
Lai, K. A., Sheshadri, A., Adrianza, A. M., Etchegaray, M., Balachandran, D. D., Bashoura, L., Shannon, V. R., & Faiz, S. A. (2020) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-20-22 · Cited by 25
Immune checkpoint inhibitors: An emergency medicine focused review
Yoo, M. J., Long, B., Brady, W. J., Holian, A., Sudhir, A., & Gottlieb, M. A. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.08.038 · Cited by 21
Nikita, N., Banks, J., Keith, S. W., Song, A. J., Johnson, J. M., Wilson, M. A., Sharma, S., & Lu-Yao, G. L. (2022) · Cancers · doi:10.3390/cancers14051296 · Cited by 20
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Gallego-Plazas, J., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2023.10.009 · Cited by 25
Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer
Ni, R., Hu, Z., & Tao, R. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117430 · Cited by 23
Bai, R., Li, L., Chen, X., Chen, N., Song, W., Zhang, Y., Lv, Z., Han, F., Zhao, Y., Li, W., et al. (2021) · Journal of Oncology · doi:10.1155/2021/9935076 · Cited by 20
“On the other hand, due to the specific targets and mechanisms of action of ICIs, they may attack normal tissues and organs of the human body while activating the immune system, causing autoimmune and inflammatory effects at the corresponding sites, known as immune-related adverse events (irAEs) [10].”
BackgroundRapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo
Mu, W., Tomer, S., Harding, J. S., Kedia, N., Rezek, V. K., Cook, E., Patankar, V., Carrillo, M. A., Martin, H. A., Ng, H. L., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185489 · Cited by 20
“…transiently (16, 17), ICB treatment can lead to serious side effects, such as onset of type 1 diabetes and colitis and other adverse effects (18, 19) that may be unacceptable to that may be unacceptable to ART-treated people living with HIV Chimeric antigen receptor (CAR) T cell therapy shows…”
Wang, H., Yeh, T., Chan, L., Hsu, C., & Cho, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207621 · Cited by 20
Tittel, S. R., Laubner, K., Schmid, S. M., Kress, S., Merger, S. R., Karges, W., Wosch, F. J., Altmeier, M., Pavel, M., Holl, R. W., et al. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13215 · Cited by 19
“Among the most common immune-related adverse events are colitis, hepatitis, and hypothyroidism; more rarely adrenal failure and autoimmune diabetes.(3,6,7) CPI-induced diabetes mellitus (CPI-DM) has most frequently been reported with anti-PD-1 or anti-PD-L1 therapy whereas DM due to anti-CTLA-4 therapy is very rare.”
BackgroundRefractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
Nogal, G. P. D., & Patel, N. (2022) · ACG Case Reports Journal · doi:10.14309/crj.0000000000000946 · Cited by 17
Azhar, M. U., Abrencillo, R., Gandhi, S. J., Altan, M., & Sheshadri, A. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000975 · Cited by 17
“However, ICIs cause a rangeof side effects innearlyhalf ofpatients, someof which can be extremely deadly [3].”
BackgroundLi, H., Zheng, Y., Li, B., Zhi, Y., Chen, M., Zeng, J., Jiao, Q., Tao, Y., Liu, X., Shen, Z., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20028 · Cited by 17
“Several case reports have discussed the potential relationship between ICIs and myocarditis [43, 44].”
Bioactive lipids as modulators of immune check point inhibitors
Das, U. N. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109473 · Cited by 18
Pradeep, J., Win, T. T., Aye, S. N., & Sreeramareddy, C. T. (2022) · Journal of Cancer · doi:10.7150/jca.72210 · Cited by 17
“Cessation of the ICIs, initiation of steroids and supportive therapy were the preferred choice of treatment for those AEs [62, 63].”
BackgroundTaniguchi, S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060566 · Cited by 17
Immunogenic properties of immunoglobulin superfamily members within complex biological networks
Odales, J., Valle, J. G., Martínez‐Cortés, F., & Manoutcharian, K. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104235 · Cited by 17
Lessomo, F. Y. N., Wang, Z., & Mukuka, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1080998 · Cited by 20
“In addition, some cases may not have been reported to State drug enforcement authorities (34).”
BackgroundImmune checkpoint inhibitor induced colitis: A nationwide population-based study
Farha, N., Alkhayyat, M. M., Lindsey, A. S., Mansoor, E., & Saleh, M. A. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101778 · Cited by 15
Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification
Ashkar, M. H., Chandra, S., Vege, S. S., Takahashi, H., Takahashi, N., & McWilliams, R. R. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03295-1 · Cited by 14
“Common gastrointestinal irAEs are well reported and often reversible if recognized and treated early [6, 9, 10], but”
BackgroundUpdates in drug-induced acute pancreatitis
Alhaddad, O., Elsabaawy, M., Elfauomy, M., Elsabaawy, D. M., & Mansour, T. (2020) · Egyptian Liver Journal · doi:10.1186/s43066-020-00059-3 · Cited by 15
“The older tyrosine kinase inhibitors (TKIs), sorafenib, sunitinib, and imatinib are reported to cause pancreatitis [32].”
BackgroundDeligiorgi, M. V., & Trafalis, D. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087630 · Cited by 13
“Alarmingly, the most common clinical presentation of irDMis DKA with a varying frequency ranging from approximately 50% to 100% [19,52,54,55,61,63,95,101,102].”
BackgroundImmunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies
Kong, Y., Wang, X., & Qie, R. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1347140 · Cited by 14
Oral mucositis—case series of a rare adverse effect associated with immunotherapy
Sheth, H., Pragya, R., Kovale, S., Deshpande, M., Mistry, R., Shreenivas, A. V., & Limaye, S. A. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-05993-5 · Cited by 15
Optimizing In Situ Vaccination During Radiotherapy
Yasmin‐Karim, S., Wood, J., Wirtz, J., Moreau, M., Bih, N., Swanson, W., Muflam, A., Ainsworth, V., Ziberi, B., & Ngwa, W. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.711078 · Cited by 13
HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency
Ono, M., Fukuda, I., Nagao, M., Tomiyama, K., Okazaki‐Hada, M., Shuto, Y., Kobayashi, S., Yamaguchi, Y., Nagamine, T., Nakajima, Y., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01231-1 · Cited by 14
The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship
Alabdaljabar, M. S., Durani, U., Thompson, C. A., Constine, L. S., & Hashmi, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26719 · Cited by 15
“Other more serious effects are related to autoimmune inflammatory conditions, such as colitis, hepatitis, adrenocorticotropic hormone insufficiency, hypothyroidism, type I diabetes, acute kidney injury, and myocarditis.(86) The treatment in many cases included CPI cessation, steroid initiation, and supportive therapy.”
BackgroundEndocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Immunotherapy · doi:10.2217/imt-2019-0132 · Cited by 13
Chen, J., Alduais, Y., & Chen, B. (2021) · Cell Transplantation · doi:10.1177/09636897211041587 · Cited by 12
Immune-Related Adverse Drug Reactions and Immunologically Mediated Drug Hypersensitivity
Macy, E. M. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.06.003 · Cited by 12
Walters, A. A., Dhadwar, B., & Al‐Jamal, K. T. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103624 · Cited by 14
“The use of monoclonal antibodies is associated with a range of potentially fatal adverse effects including colitis, pneumonitis, and hepatitis caused by excessive immune activation [15,16].”
BackgroundEffectiveness of immunological agents in non‐small cell lung cancer
Rekulapelli, A., Flausino, L. E., Iyer, G., & Balkrishnan, R. (2022) · Cancer Reports · doi:10.1002/cnr2.1739 · Cited by 10
Webster, K., O'Connor, M. L., Hansen, A. R., Kircher, S. M., Jim, H., Dicker, A. P., Janda, M., Ala‐Leppilampi, K., Bingham, C. O., Feliciano, J. L., et al. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.38 · Cited by 12
“Our literature review yielded 25 articles documenting irAE incidence, management guidelines, toxicity profiles, and associated symptomatology([4,9,11-15,40-57]).”
BackgroundCMV coinfection in treatment refractory immune checkpoint inhibitor colitis
Harris, K. B., Funchain, P., & Baggott, B. B. (2020) · BMJ Case Reports · doi:10.1136/bcr-2019-233519 · Cited by 11
Makunts, T., Burkhart, K., Abagyan, R. A., & Lee, P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263402 · Cited by 11
“The use of the checkpoint inhibitors has been linked to significant immune-related adverse events (irAEs) [5, 6] affecting multiple organ systems and leading to irAEs such as colitis, pancreatitis, hepatitis, thyroiditis, hypophysitis, and rare but potentially fatal toxicities such as myocarditis.”
BackgroundPage, D. B., Pucilowska, J., Chun, B., Kim, I., Sanchez, K. G., Moxon, N., Mellinger, S. L., Wu, Y., Koguchi, Y., Conrad, V. K., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00541-2 · Cited by 14
“…and clinically active in metastatic TNBC. Treatment discontinuation rates due to toxicity were similar to those observed with capecitabine 30 or paclitaxel monotherapy 31 , and consistent with the low rates of immune-related adverse events observed in phase III chemoimmunotherapy trials 32 – 34 .”
Yong, J., Gröger, S., von Bremen, J., Meyle, J., & Ruf, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911405 · Cited by 10
“Given the importance of PD-1 in suppressing self-reactive T cell-mediated immune responses, immunosuppression caused by the PD-1/PD-L1 immune checkpoint inhibitors can result in the infiltration of T cells into organs all over the body, causing an immune response [93].”
BackgroundValentine, J. C., Hall, L., Spelman, T. D., Verspoor, K. M., Seymour, J. F., Rischin, D., Thursky, K., Slavin, M. A., & Worth, L. J. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05439-4 · Cited by 10
Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis
Shieh, C., Chalikonda, D., Block, P., Shinn, B., & Kistler, C. A. (2020) · Annals of Gastroenterology · doi:10.20524/aog.2020.0552 · Cited by 12
“Typical GI irAEs noted include immune-mediated colitis (8-22%), hepatotoxicity (4-11%), pancreatitis (10-15%), and non-specific symptoms of nausea, vomiting and diarrhea (27-54%) [5-7].”
BackgroundMethod18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor–Related “Retroperitoneal Panniculitis”
Minutoli, F., Parisi, S., Laudicella, R., Pergolizzi, S., & Baldari, S. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003806 · Cited by 9
Njonnou, S. R. S., Aspeslagh, S., Essomba, M.-J. N., Racu, M.-L., Lekpa, F. K., & Vandergheynst, F. A. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03663-6 · Cited by 9
“The endocrine system is the most commonly affected in the course of ICI treatment [25].”
BackgroundPeriocular and ocular surface nonmelanoma skin cancer
Hooper, J., Shao, K., Feng, P. W., Falcone, M., & Feng, H. (2023) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2023.10.011 · Cited by 9
Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
Anson, D. M., Norton, J. A., Chaucer, B., & Bansal, S. K. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/7896749 · Cited by 9
“Other documented, serious adverse effects include hepatitis, adrenal insufficiency, hypothyroidism, pancreatic dysfunction, and myocarditis [4].”
BackgroundBispecific anti-PD-1/CTLA-4 Antibody for Advanced Solid Tumors
Pérez-Santos, M. (2020) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2020-0017 · Cited by 9
Huang, B.-C., Lu, Y., Liao, J., Liu, H.-J., Hong, S.-T., Hsieh, Y.-C., Chuang, C.-H., Chen, H.-J., Liao, T.-Y., Ho, K., et al. (2021) · Chemical Science · doi:10.1039/d1sc01748a · Cited by 9
HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysis
Ono, M., Nagao, M., Takeuchi, H., Fukunaga, E., Nagamine, T., Inagaki, K., Fukuda, I., & Iwabu, M. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae081 · Cited by 8
Lu, D., Yuan, L., Wang, Z., Xu, D., Meng, F., Jia, S., Li, Y., Li, W., & Nan, Y. (2025) · Free Radical Research · doi:10.1080/10715762.2025.2515202 · Cited by 9
“…symptoms, which may affect their quality of life [11]. although immunotherapy has great potential compared to traditional therapies, it still induce auto-immune toxicity or encephalopathic syndromes [12– 15]. therefore, the prevention and treatment of gastric cancer is still serious.”
Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report
Dang, H., Sun, J., Wang, G., Renner, G. J., Layfield, L. J., & Hilli, J. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i18.4100 · Cited by 8
Jiang, Q., & Xue, R. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i3.577 · Cited by 7
A Real-World Comparison of the Safety Profile for Immune Checkpoint Inhibitors in Oncology Patients
Alwhaibi, A. M., Alenazi, M. A., Alghadeer, S. M., Mansy, W., Alsaif, R., Abualreesh, N. E., Alanazi, R. J., Alroumi, A., & Alanazi, S. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020388 · Cited by 9
Immune checkpoint inhibitor-associated pneumonitis: focus on diagnosis and underlying mechanisms
Khoury, M., Faiz, S. A., & Sheshadri, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001175 · Cited by 10
Metadata
- Authors
- Bajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., Levitt, M., Asif, A., & Hossain, M. A.
- Affiliations
- Jersey Shore University Medical Center (US)
- Corresponding author
- Gupta, Varsha
- Venue
- Journal of Clinical Medicine Research
- Publisher
- Elmer Press, Inc.
- Published
- 2019
- Volume
- 11
- Issue
- 4
- Pages
- 225-236
- ISSN
- 1918-3003 (ISSN-L)
- 1918-3011
- PMC
- PMC6436564
- OpenAlex
- W2921474571
- Cited by
- 179
- References
- 123
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 16 · 2023: 13 · 2022: 21 · 2021: 40 · 2020: 53 · 2019: 8
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Journal of Clinical Medicine Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitors, immune-related adverse events, PD-1 inhibitors, CTLA-4 inhibitors, nivolumab, pembrolizumab, ipilimumab, colitis, hepatitis, adrenal insufficiency, hypothyroidism, type 1 diabetes, diabetic ketoacidosis, acute kidney injury, myocarditis, pancreatic dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.